Preserved T-cell Response in anti-CD20 Treated Multiple Sclerosis Patients Following SARS-CoV-2 Vaccination

Abstract

The SARS-CoV-2 pandemic has tremendous implications for the management of patients with autoimmune conditions such as multiple sclerosis (MS) under immune therapies targeting CD20+ B cells (aCD20). We here investigated humoral and cellular immune responses, including neutralization against SARS-CoV-2 WT and delta variant and T cell responses of aCD20-treated MS patients following SARS-CoV-2 vaccination compared to healthy controls. aCD20-treated MS patients had lower anti-SARS-CoV-2-Spike titers, which correlated with B-cell repopulation. Sera of aCD20 treated patients had reduced capacity to neutralize WT and delta pseudoviruses in vitro. On the contrary, aCD20 treated patients elicited higher frequencies of CD3+ T cells, Th1 cells, Th2 cells, Tc1 cells and CD8+IFN-γ+IL-2+ cells. In summary, aCD20 treated patients have a reduced humoral immune response, depending on B cell repopulation, in accordance with a shift of cellular immune response to a stronger Th1, Th2 and Tc1 phenotype, suggesting strong cellular protection against SARS-CoV-2.

Immune response in ofatumumab treated multiple sclerosis patients after SARS-CoV-2 vaccination

“…For PBMC restimulation with SARS-CoV-2 peptide mix, the cryopreserved cells were thawed, counted and 80 µL of a 2.5*10 6 cells per ml cell suspension seeded in duplicates in a 96 well plate in OpTmizer ™ CTS ™ (Thermofisher) medium ( 10 ). Following a resting time of 2 hours (h), the stimulation was induced with 2 µg/ml PepMix SARS-CoV-2 (JPT) for 16-18 h under the presence of Brefeldin A solution (BioLegend).…”